Newsletter Archives - Hamlet BioPharma

Jul

2026

Pressrelease – Lund, 17 Juli, 2026 – Uppdatering inför ordinarie teckningsperiod för teckningsoptioner TO5B

Hamlet Biopharma

Uppdatering inför ordinarie teckningsperiod för teckningsoptioner TO5B Ordinarie teckningsperiod för teckningsoptioner av serie TO5B är mellan 20 – 31...

Jul

2026

Pressrelease – Lund, 16 Juli, 2026 – Dialogen med en ledande tysk aktör om partnerskap avseende blåscancerbehandling fortgår i mycket positiv anda

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma går nu vidare med förhandlingar om villkor och ramar för slutförande av läkemedelsutveckling och kommersialisering av Alpha1H Tillsam...

Jun

2026

Pressrelease – Lund, June 29th, 2026 – Hamlet BioPharma Receives European Regulatory Approval for Phase III Study of Alpha1H in Bladder Cancer

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma, a pharmaceutical company specializing in the development of novel treatments for cancer and infectious diseases, today announces reg...

Jun

2026

Pressrelease – Lund, 29 Juni, 2026 – Briefglance uppmärksammar Hamlet BioPharmas samarbete med Universitetet i Iowa och potentialen för behandling av svår blåscancer

Hamlet Biopharma

Newsletter, Press releases

Den digitala analysplattformen Briefglance har uppmärksammat Hamlet BioPharma och samarbetet med Universitetet i Iowa kring utvecklingen av Alpha1H fö...

Jun

2026

Pressrelease – Lund, June 25th, 2026 – Hamlet BioPharma secures drug manufacturing at Phase III quality and release of Alpha1H for distribution to clinical trial sites

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma today announces the successful release of the Phase III quality batch of Alpha1H for use in clinical trials of bladder cancer in Euro...

Jun

2026

Pressrelease – Lund, June 23rd, 2026 – Hamlet BioPharma’s monthly digital investors’ meeting on June 30th

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 30th of June 2026, at 12:00. Please click on the link below to partic...

Jun

2026

Press release – Lund, June 22th, 2026 – Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for ...

Jun

2026

Press release – Lund, June 17th, 2026 – Pre-initiation visit in Prague, for the Phase III trial of Alpha1H in bladder cancer

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma AB (publ) today conducted a pre-initiation visit at the Department of Urology at Charles University, Prague, led by Professor Marek B...

Jun

2026

Press release – Lund, June 10th, 2026 – Continued success for the new anti-infective therapies developed by Hamlet BioPharma

Hamlet Biopharma

Newsletter, Press releases

The Journal of Infectious Diseases publishes the paper “Targeting the disease response with NlpD and LytM for effective non-antibiotic treatment of ur...

Jun

2026

Pressrelease – Lund, 8 juni, 2026 – Utökning av Hamlet BioPharmas kliniska samarbeten med ledande amerikanskt universitet

Hamlet Biopharma

Newsletter, Press releases

Hamlet BioPharma AB (publ) meddelar idag att bolaget inlett ett samarbete med University of IOWA, ett amerikanskt center inom uro-onkologi med fokus p...